Company / R&D Expense
Cytosorbents Corp R&D Expense History
FY2011-FY2018 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$7.7M
FY2018
5-year range
$2.4M / $7.7M
FY2014-FY2018
Trend
+139.8%
vs FY2017
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has fluctuated over the past 8 years, ranging from $2M in FY2016 to $8M in FY2018.
Based on SEC 10-K filings.
$8M in FY2018 with a 5-year CAGR of +25.0%.
Improved from $2M to $8M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +25.9%
- 5-Year CAGR
- +25.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +25.0%, indicating consistent growth.
- In FY2018, r&d expense increased 139.8% year-over-year.
- Lowest r&d expense in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -4.61 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2018 | $7.7M | +139.8% |
| FY2017 | $3.2M | +32.5% |
| FY2016 | $2.4M | -37.2% |
| FY2015 | $3.9M | +59.2% |
| FY2014 | $2.4M | -4.0% |
| FY2013 | $2.5M | +0.0% |
| FY2012 | $2.5M | -12.3% |
| FY2011 | $2.9M | - |
As of FY2018 · SEC 10-K · Updated Jun 24, 2026